BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

As new mutations to SARS-CoV-2 emerge faster than many countries can vaccinate their populations,  pressure is mounting on vaccine developers to pre-empt the variants before they take hold, let alone are properly characterized. And while...
BioCentury | Feb 4, 2021
Product Development

Preclinical antiviral strategies for COVID-19: Data Byte

Behind the mAbs and repurposed antivirals in development for COVID-19 are at least 44 early stage small molecule, protein and oligonucleotide therapies that could find utility should SARS-CoV-2 become endemic or another coronavirus make the jump...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting CTSC to treat lung-metastatic breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibiting the lysosomal cysteine protease CTSC could suppress breast cancer lung metastases by blocking neutrophil extracellular trap (NET) formation. In patients, high breast tumor levels of CTSC protein were associated with...
BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

As the first disease-modifying therapies for osteoarthritis enter late-stage development, companies are testing new endpoints that can capture effects on joint structure instead of relying on traditional pain-related readouts. Most are converging on MRI imaging...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...
BioCentury | Dec 8, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million on Dec. 7 in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
BioCentury | Dec 7, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed investors. Lumicell said...
Items per page:
1 - 10 of 172